A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions
A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions
Advanced Colorectal Carcinoma
DRUG: APR003
Primary Outcome Measure, Determine Maximum Tolerated Dose and/or Recommended Dose within the test APR003 dose range, Up to one year
Secondary Outcome, Overall Response Rate, Up to three years
APR003 is a small molecule TLR7 agonist that concentrates in the GI, and liver with limited systemic exposure. It is designed to increase the therapeutic window of a TLR7 agonist by minimizing the side-effects associated with generalized systemic immune activation and inflammation.